Articles
Atypical antidepressants
Content
How atypical antidepressants work
Atypical antidepressants approved by the FDA
Possible side effects of atypical antidepressants
Safety issues
Suicide risk and antidepressants
Stopping treatment with atypical antidepressants
Finding the right antidepressant
Atypical antidepressants approved by the FDA
The Food and Drug Administration (FDA) approved these atypical antidepressants to treat depression:
- Bupropion (Wellbutrin SR, Wellbutrin XL, others)
- Mirtazapine (Remeron)
- Nefazodone
- Trazodone
- Vilazodone (Viibryd)
- Vortioxetine (Trintellix)
A new antidepressant called esketamine (Spravato) is FDA approved for treatment-resistant depression. It's a nasal spray intended for use in combination with an oral antidepressant.